Lisata Therapeutics adds Tarsus eye care CFO Jeff Farrow to board

Lisata Therapeutics, Inc. announced the appointment of Jeffrey Farrow to its Board of Directors effective October 13, 2026. Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members, and was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee, with a seat also on the Audit Committee.¹ The Board has determined that Mr. Farrow is independent under Nasdaq listing rules.¹

Mr. Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a commercial-stage eye care company, a role he has held since April 2023.¹ He is also a director of Clover Biopharmaceuticals, Ltd. (HKEX) and of Achieve Life Sciences, Inc. (Nasdaq: ACHV), where he chairs the audit committee and sits on the nominating and corporate governance committee.¹

His earlier career included several finance leadership roles at companies that were later acquired. From 2016 to 2022, Mr. Farrow was Chief Financial Officer of Global Blood Therapeutics, Inc. through the company's acquisition by Pfizer Inc.¹ He previously served as CFO of ZS Pharma, Inc. through its acquisition by AstraZeneca in 2015, and as CFO of Hyperion Therapeutics, Inc. from 2010 until its acquisition by Horizon Therapeutics in 2015.¹ Earlier, Mr. Farrow held finance leadership roles at Evotec AG and at Renovis, Inc., where he was vice president of finance and chief accounting officer, and he began his career with seven years in the audit practice of KPMG LLP.¹

The appointment comes as Lisata advances its clinical pipeline. Following its acquisition of Marea Therapeutics, Lisata's lead product candidate is MAR001, in Phase 2b development for severe hypertriglyceridemia, while the company is also advancing MAR002 for acromegaly.¹